This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weiss, R. B. Search for Related Content PubMed PubMed Citation Articles by Weiss, R. B.

The Randomized Trials of Dose-Intensive Therapy for Breast Cancer: What Do They Mean for Patient Care and Where Do We Go From Here?

Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA

Correspondence: Raymond B. Weiss, MD, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, 20007-2126, USA. Telephone: 301-929-1159; Fax: 301-929-9377; e-mail: RayWeissMD{at}aol.com

At the May 1999 meeting of the American Society of Clinical Oncology (ASCO), results of some of the randomized trials conducted in the 1990s assessing the value of high-dose (dose-intensive) therapy for breast cancer were presented. The number of women treated with such therapy has grown almost exponentially since the early 1990s so that breast cancer is now the most common malignancy treated with stem cell transplant. At the same time the cost of such treatment (from $60,000 upwards to $150,000) has caused it to become the most controversial issue in all of medical oncology during this past decade. Does such therapy truly provide a benefit to women with breast cancer, and is it therefore a therapy that should be routinely offered to suitable patients? This article will attempt to put this issue in some perspective with emphasis on the recently reported randomized studies of this treatment for both early-stage and metastatic disease. In addition, some comments will be made regarding where research regarding this topic will likely be focused in the next few years.

Key Words. Breast cancer • Dose-intensive therapy • Randomized studies

This article has been cited by other articles:

				R. B. Weiss, G. G. Gill, and C. A. Hudis An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications J. Clin. Oncol., June 1, 2001; 999(1): 1 - 8. [Abstract] [Full Text]

				R. B. Weiss, G. G. Gill, and C. A. Hudis An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications J. Clin. Oncol., June 1, 2001; 19(11): 2771 - 2777. [Abstract] [Full Text] [PDF]